Cassava Sciences again under scrutiny over Alzheimer's drug research

seekingalpha03-12

A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2418343125?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413289936/image_1413289936.jpg","is_english":true,"pubTime":"2024-03-12 07:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2418343125","market":"sh","top_or_hot":-1,"title":"Cassava Sciences again under scrutiny over Alzheimer's drug research","media":"seekingalpha","content":"<div>\n<p>A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September ...</p>\n\n<a href=\"https://seekingalpha.com/news/4078244-cassava-sciences-again-under-scrutiny-alzheimers-drug-research-simufilam\">Source Link</a>\n\n</div>\n","source":"seekingalpha_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cassava Sciences again under scrutiny over Alzheimer's drug research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCassava Sciences again under scrutiny over Alzheimer's drug research\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-12 07:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4078244-cassava-sciences-again-under-scrutiny-alzheimers-drug-research-simufilam><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September ...</p>\n\n<a href=\"https://seekingalpha.com/news/4078244-cassava-sciences-again-under-scrutiny-alzheimers-drug-research-simufilam\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SAVA","symbol_name":"Cassava Sciences Inc","start_time":0,"source_url":"https://seekingalpha.com/news/4078244-cassava-sciences-again-under-scrutiny-alzheimers-drug-research-simufilam","article_id":"2418343125","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413289936/image_1413289936.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2418343125","pubTimestamp":1710198908,"sourceInfo":{"source_id":"seekingalpha_hot_news","name":"SeekingAlpha"},"weMediaInfo":null,"summary":"A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September 2","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SAVA":"Cassava Sciences Inc","BK4547":"WSB热门概念","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4007":"制药"},"translate_title":"木薯科学再次受到阿尔茨海默氏症药物研究的审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAVA":1},"content_text":"A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's candidate simufilam was flagged with a multitude of issues during a September 2022 US FDA inspection. In that lab, Hoau-Yan Wang and his associates had evaluated samples of blood and cerebrospinal fluid from individuals who had been taking part in a simufilam trial. The FDA inspection report, obtained by Science magazine, found that Wang neglected to conduct routine calibration of equipment to make sure experiments were accurate. Also, he neglected to complete verification experiments to ensure tests were accurate and precise. In addition, improper statistical tests used by Wang \"resulted in inaccurate determination of sample concentrations.\" The Science article also noted that CUNY initially denied the inspectors access to the lab, only acquiescing two days later. The publication of the report is likely to cast additional doubt on simufilam trial results. In a statement provided to Science, Cassava (SAVA) stated that Wang's lab is not involved in simulfilam's phase 3 program. The company said that because the lab is engaged in exploratory research, it is not required to be in compliance with FDA Good Laboratory Practices standards. \"The FDA inspection at CUNY resulted in no material change to the data generated for our benefit by this academic research lab,\" Cassava (SAVA) contended. As of 710p ET Monday, shares are down ~1% in after-hours trading More on Cassava Sciences  Cassava falls 38% on investigation into simufilam data manipulation Cassava Sciences gains after safety data for Alzheimer’s candidate Cassava Sciences Q3 costs rise amid late-stage Alzheimer’s program Cassava Sciences fully enrolls Phase 3 program for Alzheimer’s candidate","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2418343125"}